Lab Product News
News

Clinical research centre opens and $750,000 fund announced


Laval, QC – Servier Canada has officially opened a new Clinical Development Centre in Montreal, and launched a new $750,000 research fund.

The company says the new centre will focus on the design and development of Servier’s international clinical research. It will coordinate basic research projects as well as the implementation of phases I to III studies working closely with investigators such as the Montreal Heart Institute, INRS, CRCHUM and MUHC. The main therapeutic areas are cardiovascular diseases, oncology and neuropsychiatry.

We are today very proud to open the doors to our new centre for excellence in clinical development just over one year after its announcement. This $17M investment illustrates the importance of research to our growth model. We have invested a total of $100M over the past five years in Canada,” said Frédéric Fasano, CEO of Servier Canada.

At the opening, the company also announced the creation of the Dr Madeleine Tremblay Servier and Groupe Servier Fund for the Development of Medicinal Products at the Faculty of Pharmacy of the Université de Montréal. The $750,000 fund is dedicated to the education of future talent in the pharmaceutical industry and named after Dr Madeleine Tremblay Servier, born in Quebec, who graduated from UdeM’s Faculty of Pharmacy, and is internationally renowned for her distinguished career in the pharmaceutical industry. Founder of Servier Canada in 1978 and a pioneer in the international development of the group, Dr. Tremblay Servier now chairs the Collège International de Recherche Servier.

“Our new Clinical Research Centre and the Tremblay Servier Research Fund that we are inaugurating today underline our commitment to this part of the world where life sciences have a very special place and that is becoming a key platform for innovation,” said Olivier Laureau, president of Groupe Servier Group.

Servier Canada is a subsidiary of Groupe Servier and employs 161 staff in Quebec. The company says it plans to register three new products in the next three years and is currently developing its research activities in the fields of cardiovascular and neuropsychiatric diseases and solid and hematologic cancers.